Wikidata

(Q61967357)

English

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

clinical trial

In more languages

Statements

title
A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen (English)
0 references
medical condition
glioma
0 references
nausea
0 references
vomiting
0 references
main subject
aprepitant
0 references
start time
24 June 2014
0 references
end time
13 April 2017
0 references
number of participants
136
0 references
research intervention
temozolomide
0 references
dacarbazine
0 references
ondansetron
0 references
aprepitant
0 references
fosaprepitant
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61967357&oldid=2117410339"